<?xml version='1.0' encoding='utf-8'?>
<document id="26149476"><sentence text="Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction."><entity charOffset="0-9" id="DDI-PubMed.26149476.s1.e0" text="Dovitinib" /><entity charOffset="14-23" id="DDI-PubMed.26149476.s1.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26149476.s1.e0" e2="DDI-PubMed.26149476.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26149476.s1.e0" e2="DDI-PubMed.26149476.s1.e1" /></sentence><sentence text="Erlotinib is a FDA approved small molecule inhibitor of epidermal growth factor receptor and dovitinib is a novel small molecule inhibitor of fibroblast growth factor and vascular endothelial growth factor receptor"><entity charOffset="0-9" id="DDI-PubMed.26149476.s2.e0" text="Erlotinib" /></sentence><sentence text=" This phase 1 trial was conducted to characterize the safety and determine the maximum tolerated dose of erlotinib plus dovitinib in patients with previously treated metastatic non-small cell lung cancer"><entity charOffset="105-114" id="DDI-PubMed.26149476.s3.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="Escalating dose cohorts of daily erlotinib and dovitinib dosed 5 days on/2 days off, starting after a 2-week lead-in of erlotinib alone, were planned"><entity charOffset="33-42" id="DDI-PubMed.26149476.s5.e0" text="erlotinib" /><entity charOffset="47-56" id="DDI-PubMed.26149476.s5.e1" text="dovitinib" /><entity charOffset="120-129" id="DDI-PubMed.26149476.s5.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26149476.s5.e0" e2="DDI-PubMed.26149476.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26149476.s5.e0" e2="DDI-PubMed.26149476.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26149476.s5.e0" e2="DDI-PubMed.26149476.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26149476.s5.e1" e2="DDI-PubMed.26149476.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26149476.s5.e1" e2="DDI-PubMed.26149476.s5.e2" /></sentence><sentence text=" A potential pharmacokinetic interaction was hypothesized as dovitinib induces CYP1A1/1A2" /><sentence text=" Only cohort 1 (150 mg erlotinib+300 mg dovitinib) and cohort -1 (150 mg erlotinib+200mg dovitinib) enrolled"><entity charOffset="40-49" id="DDI-PubMed.26149476.s7.e0" text="dovitinib" /></sentence><sentence text=" Plasma concentrations of erlotinib were measured pre- and post-dovitinib exposure"><entity charOffset="26-35" id="DDI-PubMed.26149476.s8.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="Two of three patients in cohort 1 had a DLT (grade 3 transaminitis and grade 3 syncope)" /><sentence text=" Two of 6 patients in cohort -1 had a DLT (grade 3 pulmonary embolism and grade 3 fatigue); thus, the study was terminated" /><sentence text=" Erlotinib exposure (average Cmax 2308±698 ng/ml and AUC 0-24 41,030±15,577 ng×h/ml) approximated previous reports in the six patients with pharmacokinetic analysis"><entity charOffset="1-10" id="DDI-PubMed.26149476.s12.e0" text="Erlotinib" /></sentence><sentence text=" However, erlotinib Cmax and AUC0-24 decreased significantly by 93% (p=0"><entity charOffset="10-19" id="DDI-PubMed.26149476.s13.e0" text="erlotinib" /></sentence><sentence text="02) and 97% (p&lt;0" /><sentence text="01), respectively, during dovitinib co-administration" /><sentence text="" /><sentence text="This small study demonstrated considerable toxicity and a significant pharmacokinetic interaction with a marked decrease in erlotinib exposure in the presence of dovitinib, likely mediated through CYP1A1/1A2 induction"><entity charOffset="124-133" id="DDI-PubMed.26149476.s17.e0" text="erlotinib" /><entity charOffset="162-171" id="DDI-PubMed.26149476.s17.e1" text="dovitinib" /><pair ddi="false" e1="DDI-PubMed.26149476.s17.e0" e2="DDI-PubMed.26149476.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26149476.s17.e0" e2="DDI-PubMed.26149476.s17.e1" /></sentence><sentence text=" Given the toxicity and the pharmacokinetic interaction, further investigation with this drug combination will not be pursued" /><sentence text="" /></document>